Molecular Analysis for Therapy Choice (MATCH)
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.
The purpose of this study is to evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.
- IRB Number: 1506163289 (EAY131/MATCH)
- Research Study Identifier: TX5399
- Principal Investigator: Kathy Miller, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required